Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7992030 | 0.85 | GPR142 (0.49) | GAAMAPTGPR142BCHEHDAC1 | |
| SCHEMBL6027934 | 0.84 | L3MBTL1 (0.50) | MAPTEPHX2HDAC1KDM4E | |
| SCHEMBL18157933 | 0.76 | KDM4C (0.42) | GAAMAPTSMN1; SMN2GPR142KDM4E | |
| SCHEMBL10064622 | 0.75 | GAA (0.64) | GAAMAPTSMN1; SMN2EPHX2BCHE | |
| SCHEMBL10863579 | 0.74 | KDM4C (0.37) | GAAMAPTGPR142KDM4E | |
| SCHEMBL29937460 | 0.73 | MAOA (0.55) | GPR142 | |
| SCHEMBL27228 | 0.72 | GAA (0.95) | GAAMAPTBCHEMPOSIGMAR1 | |
| SCHEMBL15313384 | 0.72 | CYP1A2 (0.64) | — | |
| SCHEMBL10478067 | 0.71 | EPHX2 (0.54) | GAAMAPTSMN1; SMN2EPHX2BCHE | |
| SCHEMBL13258500 | 0.71 | GPR142 (0.58) | GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | GAA 419/4885MAPT 4112/4885SMN1; SMN2 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.